What is HC Wainwright’s Estimate for EPRX Q1 Earnings?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) – Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Eupraxia Pharmaceuticals in a research report issued to clients and investors on Tuesday, March 17th. HC Wainwright analyst B. Folkes forecasts that the company will post earnings per share of ($0.23) for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Eupraxia Pharmaceuticals’ current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ Q3 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.96) EPS, FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($1.05) EPS and FY2029 earnings at ($0.42) EPS.

Several other equities analysts have also recently weighed in on EPRX. Lifesci Capital upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Zacks Research downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday. Wall Street Zen lowered shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Cantor Fitzgerald upped their price target on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, January 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Eupraxia Pharmaceuticals Price Performance

Shares of Eupraxia Pharmaceuticals stock opened at $7.51 on Thursday. The company has a market capitalization of $270.06 million, a P/E ratio of -7.29 and a beta of 1.27. The business has a 50-day moving average of $8.30 and a two-hundred day moving average of $6.87. Eupraxia Pharmaceuticals has a 1 year low of $2.68 and a 1 year high of $9.32.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its earnings results on Thursday, March 19th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.21).

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Guardian Wealth Advisors LLC NC acquired a new stake in Eupraxia Pharmaceuticals in the 4th quarter valued at approximately $76,000. Aptus Capital Advisors LLC acquired a new position in Eupraxia Pharmaceuticals during the 4th quarter worth approximately $76,000. Bank of America Corp DE boosted its position in Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after acquiring an additional 10,059 shares during the last quarter. Quadrature Capital Ltd bought a new position in shares of Eupraxia Pharmaceuticals during the 2nd quarter worth approximately $61,000. Finally, TCI Wealth Advisors Inc. bought a new position in shares of Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $65,000.

Eupraxia Pharmaceuticals News Roundup

Here are the key news stories impacting Eupraxia Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $11.00 price target on EPRX, signaling continued broker conviction and implying meaningful upside from current levels. Read More.
• Positive Sentiment: Lifesci Capital kept a “Strong-Buy” rating even as it adjusted estimates, which supports continued institutional optimism about the company’s longer-term prospects. Read More.
• Neutral Sentiment: HC Wainwright published a detailed multi-year forecast schedule (quarterly 2026 estimates and longer-term FY2030 view), providing updated guidance investors can use to re-model cash needs and valuation. Read More.
• Negative Sentiment: HC Wainwright cut near- and medium-term EPS estimates sharply: FY2026 from ($0.52) to ($0.96), FY2027 to ($0.91) (from $0.55 prior), FY2028 to ($1.05) (from ($0.63)), and FY2029 to ($0.42) (from ($0.13)). Those downgrades increase short-term downside risk and reflect a worse-than-expected path to profitability. Read More.
• Negative Sentiment: HC Wainwright trimmed its prior $12 price target to $11 (still a buy), signaling a modest reduction in their valuation uplift for the stock. Read More.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.